Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer

Keyphrases

• Phase II Study 100%
• Chemoradiotherapy 100%
• Bladder 100%
• Muscle-invasive Bladder Cancer 100%
• Mitomycin C 66%
• 5-fluorouracil (5-FU) 66%
• BC2001 66%
• Diarrhea 33%
• Phase II Trial 33%
• Survival Rate 33%
• Radiotherapy 33%
• Neutropenia 33%
• Hydronephrosis 33%
• Female Patients 33%
• Dose Escalation 33%
• Long-term Treatment 33%
• Metastatic Spread 33%
• Complete Response 33%
• Treatment-related 33%
• Combined Modality Therapy 33%
• Organ Preservation 33%
• Long-term Efficacy 33%
• Thrombocytopenia 33%
• Long-term Toxicity 33%
• Muscle-invasive 33%
• Salvage Therapy 33%
• Renal Functional Reserve 33%
• Distant Progression 33%
• Bowel Toxicity 33%
• T4 Disease 33%
• Progression-free 33%
• Febrile Neutropenia 33%
• Local Progression 33%
• Bladder Dose 33%
• Cystoscopic 33%
• Cystoscopy 33%
• Intravesical Chemotherapy 33%
• Salvage Cystectomy 33%
• Dysuria 33%
• Invasive Recurrence 33%
• Early Metastatic 33%
• Glomerular Filtration Rate 33%

Medicine and Dentistry

• Chemoradiotherapy 100%
• Bladder 100%
• Muscle Invasive Bladder Cancer 100%
• Mitomycin 50%
• Fluorouracil 50%
• Biopsy Technique 25%
• Survival Rate 25%
• Recurrent Disease 25%
• Hydronephrosis 25%
• Febrile Neutropenia 25%
• Diarrhea 25%
• Progression Free Survival 25%
• Cystectomy 25%
• Thrombocytopenia 25%
• Neutropenia 25%
• Salvage Therapy 25%
• Gastrointestinal Toxicity 25%
• Glomerular Filtration Rate 25%
• Cystoscopy 25%
• Strangury 25%
• Diseases 25%
• Radiation Therapy 25%
• Phase III Trials 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Chemoradiation Therapy 100%
• Muscle Invasive Bladder Cancer 100%
• Fluorouracil 66%
• Mitomycin 66%
• Diarrhea 33%
• Chemotherapy 33%
• Recurrent Disease 33%
• Neutropenia 33%
• Hydronephrosis 33%
• Survival Rate 33%
• Febrile Neutropenia 33%
• Progression Free Survival 33%
• Thrombocytopenia 33%
• Gastrointestinal Toxicity 33%
• Strangury 33%
• Diseases 33%
• Phase III Trials 33%